CANbridge Pharmaceuticals Inc. (01228) released its Monthly Return for the period ended 31 October 2025. The authorized share capital remained 5,000,000,000 ordinary shares with a par value of USD0.00001 each, totaling USD50,000. The issued share count stood unchanged at 510,826,484.

Under the Post-IPO Share Option Scheme, 72,000 options lapsed, leaving 8,608,750 options outstanding at month-end. The number of shares that can be issued upon exercise of these options totaled 2,241,932, with the maximum issuable under the scheme at 28,185,342. Meanwhile, under the Pre-IPO Equity Incentive Plan, 21,809,308 shares remained available for potential issuance. No additional share issuance or treasury share transactions occurred during the month.